Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation
The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Myofibroblasts, the hallmark of fibrotic disease, contribute to the pathology of fibrosis by secreting large amounts of extracellular matrix and contributing to alveolar contraction. Myofibroblasts are characterized by the expression of α-smooth muscle actin (α-SMA), a contractile protein normally associated with smooth muscle cells. Transforming growth factor-β1 (TGF-β1) is a well characterized profibrotic cytokine that induces myofibroblast transformation both in vitro and in vivo. We report here that the lipid mediator prostaglandin E2 (PGE2) inhibits TGF-β1–induced expression of α-SMA in primary fetal and adult lung fibroblasts. This inhibition of α-SMA expression is associated with a reduction in the expression of collagen I. Inhibitory actions of PGE2 are mediated via E prostanoid receptor 2 (EP2) signaling, but not by EP3 signaling, and increases in cyclic adenosine monophosphate production. The inhibitory effects of PGE2 on TGF-β1–induced α-SMA expression are mimicked by an EP2 selective agonist, butaprost, and by forskolin-induced direct activation of adenyl cyclase. An EP2 antagonist blocks the inhibitory effects of PGE2, and an EP3 agonist does not inhibit TGF-β1–mediated increases in α-SMA expression. Our results demonstrate that PGE2 inhibits transition of fibroblasts to myofibroblasts by an EP2 receptor-activated pathway. Augmenting this pathway may serve as a potent antifibrotic therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 has similar effects on formation and apoptosis in lung and keloid fibroblasts (145–147).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [147]
Citations
Cites
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243 · cited 1×
“TGF-1 stimulates the expression of -SMA mRNA and protein in myofibroblasts (4, 6, 13 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 2×
“These findings support the prevailing hypothesis that fibrosis is the consequence of dysregulated repair after some form of lung injury ( 2 ).”
BackgroundKhalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505 · cited 1×
“Numerous factors have been identified as promoting the transition of fibroblasts to myofibroblasts, specifically TGF-1, granulocyte macrophage-colony stimulating factor, heparin, and TNF- (12, 29 , 30).”
BackgroundZhang, K., Rekhter, M. D., Gordon, D., & Phan, S. H. (1994) · PubMed · Cited by 480
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392 · cited 3×
“Moreover, fibroblasts cultured from idiopathic pulmonary fibrosis patients exhibit an impaired ability to synthesize PGE2 (21, 22 ), which has been attributed to an inability to appropriately upregulate COX-2 mRNA and protein levels (22, 35).”
BackgroundInfluentialSelf-citationCharacterization of a New Human Diploid Cell Strain, IMR-90
Nichols, W. W., Murphy, D. G., Cristofalo, V. J., Toji, L. H., Greene, A. E., & Dwight, S. A. (1977) · Science · doi:10.1126/science.841339 · Cited by 367 · cited 1×
“Definition of abbreviations: EP, E prostanoid receptor; RT-PCR, reverse transcriptase‐polymerase chain reaction. lung fibroblasts ( 24 ).”
Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L., & Gabbiani, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1595 · Cited by 268 · cited 3×
“Few factors have been identified that inhibit the transformation of myofibroblasts (5, 14 , 15, 31).”
BackgroundResultInfluentialFactors influencing myofibroblast differentiation during wound healing and fibrosis.
Desmoulière, A. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1090 · Cited by 265 · cited 3×
“Among the -SMA inducing factors, TGF- 1i s thought to be the most efficient ( 12 ).”
BackgroundInfluentialKeerthisingam, C. B., Jenkins, R. G., Harrison, N. K., Hernandez-Rodriguez, N. A., Booth, H., Laurent, G. J., Hart, S. L., Foster, M. L., & McAnulty, R. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64092-8 · Cited by 241 · cited 2×
“Animal models have proven that pharmacologic or genetic blockade of prostaglandin production during the evolution of bleomycin-induced pulmonary fibrosis results in worse fibrotic outcomes ( 35 , 36).”
BackgroundZhang, H.-Y., Gharaee‐Kermani, M., Zhang, K., Karmiol, S., & Phan, S. H. (1996) · Europe PMC (PubMed Central) · Cited by 235
Research works printed but not linked: 13
- 2001, Chest, 120(1 Suppl), 77S
- 1981, Am. J. Pathol., 102, 427
- 1989, Lab. Invest., 60, 643
- 1996, Am. J. Pathol., 148, 527
- 1995, Exp. Nephrol., 3, 134
- 1994, Am. J. Pathol., 145, 114
- 1995, Am. J. Pathol., 147, 352
- 1996, Kidney Int. Suppl., 54, S46
- 1985, Am. Rev. Respir. Dis., 131, 94
- 1998, J. Cell. Biochem., 71, 254, 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.0.CO;2-L · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
- 1993, Am. J. Pathol., 143, 1754
- 1992, Lab. Invest., 67, 716
- 1995, J. Rheumatol., 22, 1876
Cited by
Items 201–297 of 297
PTGES is involved in myofibroblast differentiation via HIF ‐1α‐dependent glycolysis pathway
Lin, M., Lee, Y., Liao, J., Chou, C., & Yang, Y. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70157 · Cited by 19
“51 In contrast, PGE 2 exerts profibotic effects via cyclin D expression enhancement to promote fibroblast proliferation.”
BackgroundShimokawa, M., Haraguchi, M., Kobayashi, W., Higashi, Y., Matsushita, S., Kawai, K., Kanekura, T., & Ozawa, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.035 · Cited by 17
Na+,K+-ATPase as a Target for Treatment of Tissue Fibrosis
Orlov, S. N., La, J., Smolyaninova, L. V., & Dulin, N. O. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170619105407 · Cited by 16
Aspirin-Intolerant Asthma: A Comprehensive Review of Biomarkers and Pathophysiology
Velazquez, J. R., & Teran, L. M. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8340-0 · Cited by 19
Corboz, M. R., Salvail, W., Gagnon, S., LaSala, D., Laurent, C. E., Salvail, D., Chen, K., Cipolla, D. C., Perkins, W. R., & Chapman, R. W. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106486 · Cited by 16
Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?
Thatcher, T. H., Freeberg, M. A. T., Myo, Y. P. A., & Sime, P. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108460 · Cited by 15
Manokawinchoke, J., Pimkhaokhum, A., Everts, V. E., & Pavasant, P. (2014) · Journal of Periodontal Research · doi:10.1111/jre.12162 · Cited by 19
Nakata, T. M., Suzuki, K., Uemura, A., Shimada, K., & Tanaka, R. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000652 · Cited by 15
Elhadidy, M. G., Elmasry, A., Elsayed, H. R. H., El-Nablaway, M., Hamed, S. M., Elalfy, M. M., & Rabei, M. R. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08171 · Cited by 16
Schmitz, T., Cox, L. A., Li, C., Levine, B. A., Ford, S. P., McDonald, T. J., & Nathanielsz, P. W. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e318030d141 · Cited by 15
“Interestingly, EP2 receptor has also been demonstrated to mediate PGE2-induced inhibition of the differentiation of fibroblasts into myofibroblasts that occurs during tissue repair and lung fibrosis (32).”
BackgroundWei, B., Cai, L., Sun, D., Wang, Y., Wang, C., Chai, X., Xie, F., Su, M., Ding, F., Liu, J., et al. (2014) · Molecules · doi:10.3390/molecules19044967 · Cited by 17
“So these findings indicated mPGES-1-derived PGE2 exerts a beneficial effect against lung fibrosis through EP2 receptor-mediated signaling pathway, which resembled previous research [31].”
ResultDurante, M., Sgambellone, S., Lanzi, C., Nardini, P., Pini, A., Moroni, F., Masini, E., & Lucarini, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00525 · Cited by 15
Gerarduzzi, C., He, Q., Antoniou, J., & Battista, J. A. D. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24806 · Cited by 20
“The PGE2/EP/cAMP/PKA signalling cassette has been implicated in stress fibre disassembly and changes in cellular morphology [Dong et al., 1998; Kolodsick et al., 2003; Thomas et al., 2007], although substrate specificity and functional changes in substrate activity due to post-translational…”
BackgroundInfluentialYu, D., Zhuang, Z., Ren, J., Hu, X., Wang, Z., Zhang, J., Luo, Y., Wang, K., He, R., & Wang, Y. (2019) · Regenerative Biomaterials · doi:10.1093/rb/rbz016 · Cited by 15
Nunez, F. J., Schulte, N. A., Fogel, D. M., Michalski, J., Rennard, S. I., Penn, R. B., Toews, M. L., & Ostrom, R. S. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01800-5 · Cited by 16
“Evidence that PGE2 produces antifibrotic effects is relatively clear in the literature (Kolodsick et al. 2003;White et al. 2005; Bozyk and Moore 2011).”
BackgroundSokolova, E., Hartig, R., & Reiser, G. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06511.x · Cited by 14
Kawashima, T., Yamazaki, R., Matsuzawa, Y., Yamaura, E., Takabatake, M., Otake, S., Ikawa, Y., Nakamura, H., Fujino, H., & Murayama, T. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.038 · Cited by 14
Srinivasalu, N., Lu, C., Pan, M., Reinach, P. S., Wen, Y., Hu, Y., Qu, J., & Zhou, X. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-224685 · Cited by 14
Chen, Y., Li, X., & Fan, X. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115894 · Cited by 13
Tofteng, S. S., Nilsson, L. L., Mogensen, A. K., Nørregaard, R., Nüsing, R. M., Diatchikhine, M., Lund, L. C., Bistrup, C., Jensen, B. L., & Madsen, K. (2022) · Acta Physiologica · doi:10.1111/apha.13828 · Cited by 12
Teegala, L. R., Gudneppanavar, R., Kattuman, E. E. S., Snyderman, M., Thanusha, A. V., Katari, V., Thodeti, C. K., & Paruchuri, S. M. (2023) · The FASEB Journal · doi:10.1096/fj.202300745rr · Cited by 12
Yu, I., Choi, D., Lee, H., & Cho, H. (2019) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0015-8 · Cited by 12
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors
Cattani‐Cavalieri, I., Ostrom, K. F., Margolis, J., Ostrom, R. S., & Schmidt, M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108920 · Cited by 18
Mechanistic basis for the antifibrotic actions of cAMP-based therapies
Peters-Golden, M. L., & Fortier, S. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0265-2025 · Cited by 13
Self-citationRomero, A., Cáceres, M., Arancibia, R., Silva, D., Couve, E., Martínez, C., Martínez, J., & Smith, P. C. (2014) · Journal of Periodontal Research · doi:10.1111/jre.12216 · Cited by 15
“PGE2 inhibits myofibroblastic differentiation (16) and the contraction of pulmonary fibroblasts cultured within collagen gels (17).”
BackgroundRampanelli, E., Rouschop, K. M. A., Teske, G. J. D., Claessen, N., Leemans, J. C., & Florquin, S. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00340.2013 · Cited by 11
Adenosine A3 Receptor (A3AR) Agonist for the Treatment of Bleomycin-Induced Lung Fibrosis in Mice
Sgambellone, S., Marri, S., Catarinicchia, S., Pini, A., Tosh, D. K., Jacobson, K. A., Masini, E., Salvemini, D., & Lucarini, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113300 · Cited by 11
“Although its etiology remains unknown, the condition is characterized by an increase in fibroblast proliferation and their activation into myofibroblasts with a trans-differentiation of epithelial cells and a massive formation of collagen together with other matrix components, such as fibronectin and α-smooth muscle a…”
BackgroundXu, Y., Wang, J., Pan, T., Chen, X., Xu, X., Jiang, D., & Yin, J. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2567-z · Cited by 11
Nakanishi, T., Takashima, H., Uetoko, Y., Komori, H., & Tamai, I. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249789 · Cited by 10
“In vitro studies suggest that PGE2 suppresses various metabolic capabilities of fibroblasts, including collagen production and transdifferentiation to myofibroblasts (Kolodsick et al., 2003; Moore et al., 2005; Huang et al., 2007), resulting in increased sensitivity of fibroblasts to apoptosis.”
BackgroundWound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors
Piao, Y. L., Wu, Y., Seo, S. Y., Lim, S., & Cho, H. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.09.011 · Cited by 10
Verma, P., Yalavarthi, B., Bhattacharyya, S., Khanna, D., Gudjonsson, J. E., Tsoi, L. C., Wells, R., Ross, R. L., Galdo, N. A. R., Galdo, F. D., et al. (2025) · Journal of Cell Science · doi:10.1242/jcs.264191 · Cited by 13
Amelioration of cisplatin-induced rat renal lesions by a cyclooxygenase (COX)-2 selective inhibitor
Yamamato, E., Izawa, T., Sawamoto, O., Juniantito, V., Kuwamura, M., & Yamate, J. (2011) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.12.005 · Cited by 9
Lobbins, M. L. B., Slominski, A. T., Hasty, K. A., Zhang, S., Miller, D. D., Li, W., Kim, T., Janjetović, Z., Tuckey, R. C., Scott, I.-S. O., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010367 · Cited by 9
Gerarduzzi, C., He, Q., Antoniou, J., & Battista, J. A. D. (2014) · Journal of Proteome Research · doi:10.1021/pr500495s · Cited by 10
Gerarduzzi, C., He, Q., Zhai, B., Battista, J. A. D., & Battista, J. A. D. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25412 · Cited by 12
“…been demonstrated previously involving stress fiber breakdown and cytoplasmic contraction over TGFb-induced stress fiber formation and voluminous cell bodies (Edwards et al., 1993; Dong et al., 1998; Ramakers and Moolenaar, 1998; Kolodsick et al., 2003; Bulin et al., 2005; Pelletier et al., 2005).”
BackgroundHuman airway trypsin‐like protease exerts potent, antifibrotic action in pulmonary fibrosis
Menou, A., Flajolet, P., Duitman, J., Justet, A., Moog, S., Jaillet, M., Tabèze, L., Solhonne, B., Garnier, M., Mal, H., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700583r · Cited by 10
Renaud, L., Wilson, C. L., Lafyatis, R., Schnapp, L. M., & Feghali‐Bostwick, C. A. (2024) · iScience · doi:10.1016/j.isci.2024.110010 · Cited by 9
Following the Path of CCL2 from Prostaglandins to Periostin in Lung Fibrosis
Moore, B. B. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0075ps · Cited by 8
“This leads to fibroblast activation because PGE2 normally limits TGF-b–induced myofibroblast differentiation (29, 30).”
BackgroundSelf-citationTranslating kidney fibrosis: Role of the EP2 receptor
Sands, J. M. (2019) · Acta Physiologica · doi:10.1111/apha.13318 · Cited by 8
Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Fortier, S. M., Redente, E. F., & Peters-Golden, M. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7479 · Cited by 11
Self-citationEffect of 15-hydroxyprostaglandin dehydrogenase inhibitor on wound healing
Seo, S. Y., Han, S.-I., Bae, C. S., Cho, H., & Lim, S. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.03.005 · Cited by 7
“Since myofibroblasts are not only more excellent in generating collagens than fibroblasts but also are involved in tissue contraction, formation of more myofibroblasts is more likely to generate tissue contracture or leave a scar, thus causing esthetic problems [14].”
BackgroundLi, N., Xu, Y., Chen, X., Fan, Y., & Wu, J. (2014) · Bioscience Reports · doi:10.1042/bsr20140130 · Cited by 7
Corboz, M. R., Plaunt, A. J., Malinin, V., Li, Z., Gauani, H., Chun, D., Cipolla, D. C., Perkins, W. R., & Chapman, R. W. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001174 · Cited by 6
“D2 receptor 1 (DP1), and prostaglandin E type 4 (EP4)] and PPAR receptors that provide TRE with a broad spectrum of activities on many different structural, inflammatory, and immune cells in the lungs (Kolodsick et al., 2003; Foudi et al., 2008; Frumkin 2012; Benyahia et al., 2013; Zaslona and PetersGolden, 2015; Lamb…”
BackgroundAirway and Systemic Prostaglandin E2 Association with COPD Symptoms and Macrophage Phenotype
Tejwani, V., Villabona-Rueda, A. F., Khare, P., Zhang, C., Le, A., Putcha, N., D’Alessio, F. R., Alexis, N. E., Hansel, N. N., & Fawzy, A. (2023) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.2022.0375 · Cited by 6
Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression
Moshkovitz, N., Shochet, G. E., & Shitrit, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512393 · Cited by 8
Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease
Moore, B. B., & Peters-Golden, M. L. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.1.87 · Cited by 6
Self-citationLipidmediatoren und ihre Rolle bei Entzündungen und Allergien
Stockert, K. (2020) · Springer eBooks · doi:10.1007/978-3-662-58140-7_6 · Cited by 6
“1985) , 5 die Differenzierung vom Fibroblasten zum Myofibroblasten (Bozyk und Moore 2011), 5 die Kollagenakkumulation im Lungenfibroblasten (Kolodsick et al.”
BackgroundCottin, V., Valenzuela, C., & Humbert, M. J. C. (2023) · European Respiratory Journal · doi:10.1183/13993003.00944-2023 · Cited by 6
Kim, Y. B., Yoon, Y.-S., Choi, Y. J., Park, E., & Kang, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22737 · Cited by 6
“Importantly, many studies provide evidence that these paracrine signals inhibit the fibrotic response via inhibition of the fibroblast to myofibroblast transition [16].”
BackgroundLipid Metabolism in Tumor-Associated Fibroblasts
Li, H., & Wan, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_8 · Cited by 6
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 122
Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
BREYER, R. M., Clapp, L. H., Coleman, R. A., Giembycz, M. A., Heinemann, Á., Hills, R., Jones, R. L., Narumiya, S., Norel, X., Pettipher, R., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f58/2019.5 · Cited by 6
Zhang, J., Vardy, E., Muise, E., Wang, T.-M., Visconti, R., Vadlamudi, A., Pinto, S., & Peier, A. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000103 · Cited by 1
“PGE2 inhibits fibroblast proliferation and myofibroblast activation via EP2 and PKA-dependent, Smad-independent pathway (Lama et al., 2002; Kolodsick et al., 2003; Thomas et al., 2007; Wettlaufer et al., 2016).”
BackgroundPark, A.-M., Hayakawa, S., Honda, E., Mine, Y., Yoshida, K., & Munakata, H. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.12.012 · Cited by 4
Anti-scarring effects of butaprost on human subconjunctival Tenon’s fibroblasts
Shin, J. H., Seo, J. H., Jung, J. H., & Kim, T. W. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.07.02 · Cited by 4
Control of lung myofibroblast transformation by monovalent ion transporters
Dulin, N. O., Smolyaninova, L. V., & Orlov, S. N. (2019) · Current topics in membranes · doi:10.1016/bs.ctm.2019.01.002 · Cited by 3
Reed, E. B., Sitikov, A. S., Shin, K. W. D., Hamanaka, R. B., Çetin-Atalay, R., Mutlu, G. M., Mongin, A. A., & Dulin, N. O. (2024) · Biochemical Journal · doi:10.1042/bcj20240317 · Cited by 5
Im, D. Y., & Lee, K. I. (2014) · Korean Journal of Medicinal Crop Science · doi:10.7783/kjmcs.2014.22.6.457 · Cited by 3
“Many studies have reported that PGE2 is an important mediator of dermal wound healing (Kolodsick et al., 2003; Savla et al., 2001).”
Background“Yap”-ing about the Antifibrotic Benefits of Prostacyclin
Huang, S. K. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0392ed · Cited by 3
“PGE2 inhibits all aspects of fibroblast function, including matrix production, fibroblast survival (4) and proliferation (5), and myofibroblast differentiation (6).”
BackgroundLuteal fibroblasts produce prostaglandins in response to IL1β in a MAPK-mediated manner
Monaco, C. F., Jones, C. M., Sayles, H. R., Rudloff, B., McFee, R. M., Cupp, A. S., & Davis, J. S. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112420 · Cited by 2
“Although prostaglandins have been implicated in fibrosis, it is believed that PGE 2 exerts an anti-fibrotic function (Li et al., 2021), as in vitro studies have shown that PGE 2 can inhibit TGF β 1-induced myofibroblast differentiation (Kolodsick et al., 2003; Thomas et al., 2007).”
Epigenetics of the pathogenic myofibroblast in lung disease
Bernau, K., Sandbo, N. K., & Brasier, A. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00018-9 · Cited by 2
Xu, C., Luo, Y., Cai, Z., Ji, J., Guo, Z., Cai, Z., You, C., Zhou, Y., Chen, Z., Zhang, W., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.06.019 · Cited by 8
“…of inflammation secreted by macrophages, has been reported to act as an inhibitor of the transformation of fibroblasts into myofibroblasts driven by TGF-β 1 during lung fibrosis [18], indicating a potent antifibrotic therapeutic strategy for PGE2 in modulation of tendon graft ligamentization.”
Interstitial lung disease-associated pulmonary hypertension – what the future holds
Cottin, V., Diesler, R., Turquier, S., & Valenzuela, C. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000992 · Cited by 2
Is Understanding Fetal Wound Repair the Holy Grail to Preventing Scarring?
Branford, O. A., & Rolfe, K. J. (2017) · Wiley eBooks · doi:10.1002/9781119282518.ch17 · Cited by 3
Modeling Fibrosis in Three-Dimensional Organoids Reveals New Epithelial Restraints on Fibroblasts
Chanda, D., & Thannickal, V. J. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0153ed · Cited by 3
“Although PGE2 has been shown to be decreased in the lungs of subjects with idiopathic pulmonary fibrosis (11), SHH signaling appears to be (paradoxically) elevated (5, 12).”
BackgroundSelf-citationDiscovery of novel anti-fibrotics through phenotypic screening
Lapthorn, A. R., Harding, S. L., Feltham, K. M., Ilg, M. M., & Cellek, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104450 · Cited by 1
LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma
Giorgio, C. D., Sette, M. R., Sensini, B., Giannelli, E., Lachi, G., Marchianò, S., Paniconi, F., Massa, C., Urbani, G., Gregorio, R. D., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117707 · Cited by 1
Tsugeno, Y., Sato, T., Watanabe, M., Furuhashi, M., & Ohguro, H. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0011 · Cited by 1
“64 It should be noted that we observed similar effects on ECM proteins and their modulators, TIMPs, MMPs between FP receptor agonists, and the EP2 agonist, OMD of 2D or 3D cultured HconF cells.”
Mendez, L., Ibáñez, B., Rodríguez, S., Wong, Y. S., Caamaño, D., Navarrete, F. I., Cabezas, J. G., Mançanares, A. C. F., Escudero, C., Rodriguez-Alvarez, L., et al. (2025) · Molecular Reproduction and Development · doi:10.1002/mrd.70053 · Cited by 1
“Numerous studies (Kolodsick et al. 2003; Huang et al. 2007; Garrison et al. 2013; Lacy et al. 2019) have reported that PGE2 treatment of myofibroblasts increases cAMP levels, stimulating EP2/EP4 receptors, TGF ‐ β 1 ‐ mediated expression of α ‐ SMA, and collagen I levels.”
Effect of thiazolidinedione phenylacetate derivatives on wound-healing activity
Park, S. H., Choi, D., & Cho, H. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1041-3 · Cited by 1
Special Delivery: A New Package for an Old Antifibrotic Mediator
Penke, L. R. K., & Peters-Golden, M. L. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0312ed · Cited by 1
“Finally, the inhibitory effects of the EVs were also abrogated by treating recipient fibroblasts with an antagonist to the E prostanoid 2 (EP2) receptor, the specific G protein–coupled receptor that is known to mediate most of the fibroblast-suppressive actions of PGE2, including its ability to inhibit myofibroblast d…”
BackgroundSelf-citationProstaglandin E₂ Reverses Myofibroblast Differentiation in Eosinophilic EsophagitisPreprint
Teranishi, R., Itami, T., Sasaki, M., Kennedy, K. V., Zhou, Y., Umeweni, C. N., McMillan, E. A., Anandakrishnan, A., Lee, R., Dhakal, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.702012 · Cited by 1
Díaz, C., & Elizabeth, M. (2014) · Universidad de Chile
Vannella, K. M. (2009) · Deep Blue (University of Michigan)
Hofmann, A., Mattyasovszky, S. G., Müller, L. P., Martin, A., Wollstädter, J., Ritz, U., Ackermann, A., Brochhausen, C., Meurer, A., & Rommens, P. M. (2007) · Obere Extremität · doi:10.1007/s11678-007-0059-9
Swaney, J. S. (2005) · eScholarship (California Digital Library)
PAPEL ANTI-FIBRÓTICO DE PGE2 E BMP-7 NA ASMA ALÉRGICA EXPERIMENTAL
Jancar, S. (2012)
Koyama, N. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_14
Role of Proteases in Idiopathic Pulmonary Fibrosis
Chatterjee, S., Chakraborty, K., Moitra, S., & Bhattacharyya, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_22
The Role of Mesenchymal Stromal Cells in Inflammation and Treatment of Pulmonary Fibrosis
Cahill, E. (2014) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Regulation of Phosphodiesterases by profibrotic reg ulators
Julia, E. S. (2008)
Jones, R. L. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61358-3
Critical role of Gα12 and Gα13 proteins in TGF-β-induced myofibroblast differentiationPreprint
Reed, E. B., Sitikov, A. S., Hamanaka, R. B., Çetin-Atalay, R., Mutlu, G. M., Mongin, A. A., & Dulin, N. O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596473
Prostaglandin E1 (PGE1) in renal transplantation
Dehnhardt, M., Leber, B., Wawrik, G., & Stiegler, P. (2025) · Transplantation Reports · doi:10.1016/j.tpr.2025.100188
Rôle de la voie hedgehog dans la fibrose pulmonaire idiopathique
Moshai, E. F. (2013) · theses.fr (ABES) · doi:10.70675/b550340ez33a1z43b7zb4eez8c2cfde874df
Ngangue, E. C.-N. (2012) · theses.fr (ABES) · doi:10.70675/b9e28642z5037z4fceza4d6za62be310d18d · Cited by 1
“Lu J, Getz G, Miska EA, varez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers.”
BackgroundImplication de FGF9 et de FGF19 dans la fibrose pulmonaire idiopathique
Justet, A. (2020) · theses.fr (ABES) · doi:10.70675/6e72f095z0cb6z4dd3zb204z88d1b08b9910
Molina, T., Fabre, P., Garcia, P., Taeyeon, K., Gurlekian, Z., Tellier, L., Rieger, L., Dallaire, J., Collette, É., Desaulniers, R., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01762-1 · Cited by 2
Cellular crosstalk of fibroblast–myofibroblast transition in intestinal homeostasis and disease
Yuan, H., Zhao, L., Xu, P., Sun, Y., Yin, K., & Wang, S. (2026) · Biomarker Research · doi:10.1186/s40364-026-00997-x
“Through PGE receptors on adjacent fibroblasts, epithe-lial-derived PGE 2 limits fibroblast migration and counteracts profibrotic activation [185, 186].”
Zhang, X., Zhong, D., Xu, Z., Li, Y., Zheng, J., Tian, Y., Qin, C., Pei, R., Wu, J., Wang, Y., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103771
BindingDB Entry 50039047: Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors.
BindingDB (2012) · UC San Diego · doi:10.7270/q2z0393h
Aldhalmi, A. K., Abdul-Hussein, B. A., Mashloosh, I. K. M., & Salman, H. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e184820
TGF-β Signaling in Fibroblasts Regulates Tumor Initiation and Progression in Adjacent Epithelia
Bierie, B., & Moses, H. L. (2011) · Springer eBooks · doi:10.1007/978-94-007-0659-0_12 · Cited by 1
Metadata
- Authors
- Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B.
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, Michigan
- Corresponding author
- Moore, Bethany B.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 29
- Issue
- 5
- Pages
- 537-544
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W1995721099
- Cited by
- 294
- References
- 37
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 7 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 16 · 2012: 15
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ca079046-03)
- National Heart, Lung, and Blood Institute (P50HL56402, HL071586, P50HL056402, P50HL60289, 2T32HL07749, R01HL071586, P50HL060289, T32HL007749)
- National Cancer Institute (CA79046)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- prostaglandin E2, myofibroblast differentiation, cyclic AMP, TGF-β1, alpha-smooth muscle actin, type I collagen, pulmonary fibrosis, antifibrotic therapy, butaprost, adenylate cyclase
- MeSH terms
- Cyclic AMP, Cell Differentiation, Fibroblasts, Colforsin, Humans, Dinoprostone, Receptors, Prostaglandin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.